Cisiv launches Baseline Plus for "real world" trials

By Gareth Macdonald

- Last updated on GMT

Related tags: Clinical research

UK software group Cisiv has unveiled a web-based EDC platform, Baseline Plus, which is specifically tailored to meet the demands of post market trials.

Observational, or post-market studies, differ from clinical trials in that they are, by definition, non-interventional and often involve a greater number of patients and physicians over a wide area.

As a result, electronic data capture (EDC) methods developed for clinical trials are often to complex to be a practical option for “real world” situations and non-specialist operators.

Outsourcing-pharma spoke with Dominic Farmer, Cisiv CEO, about how the new Baseline Plus system can help overcome such problems and how the software fits into the growing pharmaceutical industry market for post-approval observational analysis.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars